| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 604.7 | 621.3 | 643.8 |
| Other income | 49.8 | 74.8 | 62.7 |
| Total income | 654.5 | 696.1 | 706.5 |
| Profit before exceptional items & tax | 76.2 | 111.8 | 35.0 |
| Exceptional items | -18.8 | -196.3 | 0.0 |
| Profit before tax | 57.4 | -84.5 | 35.0 |
| Net profit | 51.0 | -76.4 | 21.2 |
| Operating margin | 8.8% | -12.1% | 5.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +140.60% |
|---|---|
| Revenue, year on year | -6.10% |
BSE results filing, NSE: BIOCON. Figures extracted from the filing.
Biocon Ltd: key numbers
- Share price
- ₹360.70
- Market cap
- ₹58,783 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 118.7×Sector 47.4×
- Promoter holding
- 44.68%-0.23% QoQ
- FII holding
- 8.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Biocon Bags New Order from Bahiafarma and Bionovis
Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.
- From
- Bahiafarma and Bionovis (Brazil PDP program)
- Execution
- 10 years
Biocon Other Announcement
Biocon has initiated the remittance of the final dividend for FY 2025-26. This notification confirms the dispatch process for shareholders.
Biocon Capital Structure Change
Mylan Inc. filed a revised SAST disclosure clarifying the sale of 9.19 crore shares in Biocon Limited. The seller's post-disposal holding is now correctly reported as Nil.
Biocon Regulatory Approval
Biocon received marketing approval from Japan's MHLW for its Pegfilgrastim biosimilar. This approval enhances Biocon's biosimilar portfolio and market access in Japan.
Biocon Business Update
Biocon's US subsidiary received U.S. FDA approval for the Yesintek® prefilled autoinjector. This supplemental approval enhances the company's immunology portfolio.